Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915849 · ClinicalTrials.gov registry record · Phase 1
Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01915849 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT01915849, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG LIK066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01915849
The ClinicalTrials.gov registry entry for NCT01915849 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01915849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01915849 about?
NCT01915849 is a clinical study titled "Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus". The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01915849?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2013-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01915849?
The interventions under investigation include: Placebo (DRUG), LIK066 (DRUG).
Who is sponsoring clinical trial NCT01915849?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.